

Supplementary Table 4. SF-NDI total score and scores on the five subscales of this scale in placebo and FMT-treated patients.

Time	Group	Total score	1	2	3	4	5
0	Placebo	29.1±6.2	6.2±1.6	5.5±1.7	6.7±1.7	5.3±1.9	5.3±1.7
	30-g FMT	30.1±7.2	5.3±1.9*	5.8±2.0	7.2±2.0	5.4±1.8	5.7±2.3
	60-g FMT	30.5±8.3	6.4±1.9*	5.8±2.3	7.2±1.8	5.2±2.0	5.6±2.1
2 weeks	Placebo	27.5±7.8	5.7±2.0	5.3±2.2	6.2±2.1	4.9±1.8	5.2±2.3
	30-g FMT	27.0±8.9	5.3±1.9	5.3±2.3	6.4±2.2	4.9±1.9	5.3±2.3
	60-g FMT	25.6±9.8	5.3±2.0	4.9±2.4	6.0±2.4	4.6±2.2	4.9±2.6
1 month	Placebo	28.5±6.7	6.0±1.7	4.9±2.6	6.6±1.9	5.1±1.9	5.3±1.9
	30-g FMT	24.6±8.6*	5.3±1.9	5.0±2.0	6.5±2.2	4.7±1.7	5.0±2.2
	60-g FMT	24.1±9.8*	5.0±2.1*	4.7±2.4	5.4±2.3*,*	4.4±2.0	4.7±2.6
3 months	Placebo	29.5±7.0	6.2±1.5	5.6±1.8	6.8±2.0	5.3±2.0	5.5±2.1
	30-g FMT	24.8±8.8*	5.0±1.9**	4.5±2.1*	6.1±2.1	4.4±1.7*	4.6±2.1
	60-g FMT	22.6±9.3****	4.7±2.1***	4.2±2.1**	5.2±2.3***	4.1±1.9**	4.6±2.5

Data are mean±SD values.

SF-NDI subscales: 1, tension; 2, interference with daily activities; 3, disruption to eating/drinking; 4, knowledge about/control over disease symptoms; 5, interference with work/study. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001 compared to Placebo. *, p<0.05 compared to 30-g FMT.

